CB&I Announces CATOFIN Technology Award from Shandong Chengtai

        CB&I Announces CATOFIN Technology Award from Shandong Chengtai

PR Newswire

THE WOODLANDS, Texas, April 15, 2014

THE WOODLANDS, Texas, April 15, 2014 /PRNewswire/ --CB&I (NYSE: CBI) today
announced it has been awarded a contract by Shandong Chengtai Chemical
Industry Co., Ltd. for the license and engineering design of a grassroots
iso-butane dehydrogenation unit to be built in Changyi, Shandong Province,

The unit will use the CATOFIN^® dehydrogenation technology offered from CB&I
and Clariant's tailor made CATOFIN catalyst to process iso-butane feed for the
production of 114,000 metric tons per year of isobutylene.

"The CATOFIN technology has been selected for 20 projects in the last five
years," said Daniel McCarthy, President of CB&I's Technology operating group.
"This award is further testament to the success of the CATOFIN technology and
catalyst in allowing customers to process various feedstocks at ideal
conditions for the highest yields."

"CATOFIN technology is a reliable and well proven technology. The first
commercial propane dehydrogenation unit in China was based on CATOFIN
technology and has been in successful operation since October 2013,"
highlights Stefan Heuser, Senior Vice President and Head of Business Unit
Catalysts of Clariant.

Isobutylene will be used as a building block to produce MTBE and other
downstream products.

CATOFIN is a registered trademark of Clariant.

About CB&I
CB&I (NYSE:CBI) is the most complete energy infrastructure focused company in
the world and a major provider of government services. With 125 years of
experience and the expertise of approximately 55,000 employees, CB&I provides
reliable solutions while maintaining a relentless focus on safety and an
uncompromising standard of quality. For more information, visit www.cbi.com.

About Clariant
Clariant is a globally leading specialty chemicals company, based in Muttenz
near Basel/Switzerland. On December 31, 2013 the company employed a total
workforce of 18,099. In the financial year 2013, Clariant recorded sales of
CHF 6.076 billion for its continuing businesses. The company reports in four
business areas: Care Chemicals, Catalysis & Energy, Natural Resources, and
Plastics & Coatings. Clariant's corporate strategy is based on four pillars:
managing businesses for profitability, research & development and innovation,
growth in emerging markets, and repositioning of the portfolio.

Important Information For Investors And Shareholders

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding CB&I and
represents our expectations and beliefs concerning future events. These
forward-looking statements are intended to be covered by the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties. When considering any statements that are predictive in
nature, depend upon or refer to future events or conditions, or use or contain
words, terms, phrases or expressions such as "achieve," "forecast," "plan,"
"propose," "strategy," "envision," "hope," "will," "continue," "potential,"
"expect," "believe," "anticipate," "project," "estimate," "predict," "intend,"
"should," "could," "may," "might" or similar forward-looking statements, we
refer you to the cautionary statements concerning risk factors and
"Forward-Looking Statements" described under "Risk Factors" in Item 1A of our
Annual Report filed on Form 10-K filed with the SEC for the year ended
December 31, 2013, and any updates to those risk factors or "Forward-Looking
Statements" included in our subsequent Quarterly Reports on Form 10-Q filed
with the SEC, which cautionary statements are incorporated herein by

For more information, visit www.cbi.com (http://www.cbi.com)


Website: http://www.cbi.com
Contact: Media: www.cbi.com; Investors: Christi Thoms +1 832 513 1200
Press spacebar to pause and continue. Press esc to stop.